Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 12 Jul 2019 This trial was discontinued in Slovakia (end date: 2019-06-20), according to European Clinical Trials Database.
- 10 Jul 2019 This trial was discontinued in Hungary (end date: 2019-06-20), according to European Clinical Trials Database.